Environment &
Food & Beverage
Cosmetics
Life Sciences
Metal & Mining Industry
Petrochemical & General Chemistry
Automotive Related & Interior Materials
InertSearch (Application Library)
Index
Application
LC
Document No. Index
LB301 - 400 of Application List
| No. | Description | Column |
|---|---|---|
| LB301 | Analysis of Hydrochlorothiazide (Under the Condition of the Japanese Pharmacopoeia, Candesartan cilexetil and Hydrochlorothiazide Tablets) | Inertsil ODS-4 |
| LB302 | Analysis of Candesartan cilexetil (Under the Condition of the Japanese Pharmacopoeia, Candesartan cilexetil and Hydrochlorothiazide Tablets) | Inertsil ODS-4 |
| LB303 | Analysis of Hydrochlorothiazide (Under the Condition of the Japanese Pharmacopoeia, Candesartan cilexetil and Hydrochlorothiazide Tablets) | Inertsil ODS-4 |
| LB304 | Analysis of Candesartan cilexetil (Inertsil ODS-3) (Under the Condition of the Japanese Pharmacopoeia, Candesartan cilexetil and Hydrochlorothiazide Tablets) | Inertsil ODS-3 |
| LB305 | Analysis of Candesartan cilexetil (Inertsil WP300 C18) (Under the Condition of the Japanese Pharmacopoeia, Candesartan cilexetil and Hydrochlorothiazide Tablets) | Inertsil WP300 C18 |
| LB306 | Analysis of Hydrochlorothiazide (Under the Condition of the Japanese Pharmacopoeia, Candesartan cilexetil and Hydrochlorothiazide Tablets) | Inertsil ODS-4 |
| LB307 | Analysis of Candesartan cilexetil (Under the Condition of the Japanese Pharmacopoeia, Candesartan cilexetil and Hydrochlorothiazide Tablets) | Inertsil ODS-4 |
| LB308 | Analysis of Hydrochlorothiazide (Under the Condition of the Japanese Pharmacopoeia, Candesartan cilexetil and Hydrochlorothiazide Tablets) | Inertsil ODS-4 |
| LB309 | Analysis of Voriconazole (Under the Condition of the Japanese Pharmacopoeia) | Inertsil WP300 C18 |
| LB310 | Analysis of Voriconazole (Under the Condition of the Japanese Pharmacopoeia, Voriconazole Tablets) | Inertsil WP300 C18 |
| LB311 | Analysis of Acesulfame potassium (Inertsil ODS-3) (Under the Condition of the JPE (Japanese Pharmaceutical Excipients)) | Inertsil ODS-3 |
| LB312 | Analysis of Acesulfame potassium (InertSustain C18) (Under the Condition of the JPE (Japanese Pharmaceutical Excipients)) | InertSustain C18 |
| LB313 | Analysis of Acesulfame potassium (Inertsil ODS-3) (Under the Condition of the JSFA-VIII (Japanese Standards of Food Additives)) | Inertsil ODS-3 |
| LB314 | Analysis of Acesulfame potassium (InertSustain C18) (Under the Condition of the JSFA-VIII (Japanese Standards of Food Additives)) | InertSustain C18 |
| LB316 | Simultaneous analysis of Amino acids derivatized with 4-fluoro-7-nitro-2,1,3-benzoxadiazole (NBD-F) | InertSustainSwift C18 |
| LB317 | Separation of Triacylglycerol Positional Isomer | Inertsil ODS-P |
| LB318 | Analysis of Maleic acid, Fumaric acid and Acrylic acid (InertSustainSwift C18) | InertSustainSwift C18 |
| LB319 | Analysis of Maleic acid, Fumaric acid and Acrylic acid (Inertsil WP300 C18) | Inertsil WP300 C18 |
| LB321 | Analysis of components of coffee (Inertsil ODS-4 ) | Inertsil ODS-4 |
| LB323 | Analysis of components of coffee in canned coffee (Inertsil ODS-4 ) | Inertsil ODS-4 |
| LB324 | Analysis of 16 kinds of Aldehydes (Directed by Pre-Column Method with DNPH) | InertSustainSwift C18 |
| LB325 | Analysis of Glutaraldehyde (Directed by Pre-Column Method with DNPH) | InertSustainSwift C18 |
| LB326 | Analysis of o-Phthalaldehyde (Directed by Pre-Column Method with DNPH) | InertSustainSwift C18 |
| LB327 | Analysis of Roxithromycin (Under the Condition of the Japanese Pharmacopoeia 16th edition) | InertSustainSwift C18 |
| LB328 | Analysis of Roxithromycin (Under the Condition of the Japanese Pharmacopoeia 16th edition supplement II) | InertSustainSwift C18 |
| LB329 | Analysis of Roxithromycin (Under the Condition of the Japanese Pharmacopoeia) | InertSustainSwift C18 |
| LB330 | Analysis of Roxithromycin (Under the Condition of the Japanese Pharmacopoeia) | InertSustain C18 |
| LB333 | Analysis of Amygdalin (Inertsil NH2) | Inertsil NH2 |
| LB334 | Analysis of Acrylamide, Acrylonitrile and Organic acids | Inertsil ODS-4 |
| LB335 | Analysis of Taurine derivatized with Dansyl Chloride (DNS-Cl) | InertSustain C18 |
| LB336 | Analysis of Taurine derivatized with Dansyl Chloride (DNS-Cl) | InertSustain C18 |
| LB337 | Analysis of Glyphosate, Glufosinate and AMPA derivatized with 9-Fluorenylmethyl Chloroformate (FMOC) | InertSustain C18 |
| LB338 | Analysis of Chlorhexidine gluconate solution | Inertsil ODS-4 |
| LB339 | Analysis of Rebamipide (Under the Condition of the Japanese Pharmacopoeia, Rebamipide Tablets) | InertSustain C18 |
| LB340 | Analysis of Chelating compounds | InertSustain C18 |
| LB341 | Analysis of Furfral and 5-Hydroxymethylfurfral (InertSustain C18) | InertSustain C18 |
| LB342 | Analysis of Furfral and 5-Hydroxymethylfurfral (InertSustainSwift C18) | InertSustainSwift C18 |
| LB343 | Analysis of Furfral and 5-Hydroxymethylfurfral (Inertsil ODS-4) | Inertsil ODS-4 |
| LB344 | Analysis of 6 kinds of monosaccharides and disaccharides | InertSphere Sugar-1 |
| LB345 | Analysis of 6 kinds of monosaccharides and disaccharides | InertSphere Sugar-1 |
| LB346 | Analysis of Inositol, Ribitol and Fucose | InertSphere Sugar-1 |
| LB347 | Analysis of neutral sugars and amino sugars | InertSphere Sugar-1 |
| LB348 | Analysis of Sodium Propionate (Inertsil ODS-3) | Inertsil ODS-3 |
| LB349 | Analysis of Sodium Propionate (InertSustain C18) | InertSustain C18 |
| LB350 | Analysis of 7 fatty acids (Inertsil ODS-3) | Inertsil ODS-3 |
| LB351 | Analysis of 7 fatty acids (Inertsil ODS-4) | Inertsil ODS-4 |
| LB352 | Analysis of 7 fatty acids (InertSustain C18) | InertSustain C18 |
| LB353 | Analysis of 7 fatty acids | InertSustain C18 |
| LB354 | Analysis of 7 fatty acids | InertSustain C18 |
| LB355 | Analysis of 7 fatty acids | InertSustain C18 |
| LB356 | Analysis of EPA and DHA (Inertsil ODS-3) | Inertsil ODS-3 |
| LB357 | Analysis of EPA and DHA (Inertsil ODS-4) | Inertsil ODS-4 |
| LB358 | Analysis of EPA and DHA (InertSustain C18) | InertSustain C18 |
| LB359 | Analysis of EPA and DHA | InertSustain C18 |
| LB360 | Analysis of Roxithromycin (Under the Condition of the Japanese Pharmacopoeia, Roxithromycin Tablets) | InertSustain C18 |
| LB361 | Analysis of Furfral and 5-Hydroxymethylfurfral (InertSustain AQ-C18) | InertSustain AQ-C18 |
| LB362 | Analysis of β-blocker | InertSustain AQ-C18 |
| LB363 | Analysis of Organic acid | InertSustain AQ-C18 |
| LB364 | Analysis of Water-soluble Vitamins | InertSustain AQ-C18 |
| LB365 | Analysis of Nucleoside and Nucleic acid base (InertSustain AQ-C18) | InertSustain AQ-C18 |
| LB366 | Analysis of Nucleoside and Nucleic acid base (InertSustain AQ-C18) | InertSustain AQ-C18 |
| LB367 | Analysis of Nucleoside and Nucleic acid base (InertSustain C18) | InertSustain C18 |
| LB368 | Analysis of Nucleoside and Nucleic acid base (InertSustain C18) | InertSustain C18 |
| LB369 | Analysis of Capsaicin (Under the Condition of the Japanese Pharmacopoeia, Capsicum Tincture) | InertSustain Phenyl |
| LB370 | Analysis of Prednisolone (Under the Condition of European Pharmacopoeia 8.2) | Inertsil ODS-3 |
| LB371 | Analysis of Amlodipine besilate (Under the Condition of the Japanese Pharmacopoeia, Amlodipine Besilate Orally Disintegrating Tablets) | InertSustainSwift C18 |
| LB372 | Analysis of Cyclophosphamide (Under the Condition of the Japanese Pharmacopoeia, Cyclophosphamide Tablets) | InertSustainSwift C18 |
| LB373 | Analysis of Cyclophosphamide (Under the Condition of the Japanese Pharmacopoeia, Cyclophosphamide Tablets) | InertSustainSwift C18 |
| LB374 | Analysis of Ampiroxicam (Under the Condition of the Japanese Pharmacopoeia) | Inertsil WP300 C18 |
| LB375 | Analysis of Lidocaine | InertSustain C18 |
| LB376 | Analysis of Hexamethylenetetramine (HMTA) | Inertsil HILIC |
| LB377 | Analysis of 13 kinds of Aldehydes (Directed by Pre-Column Method with DNPH) | InertSustain AQ-C18 HP |
| LB378 | Analysis of Hippuric Acids | InertSustain AQ-C18 HP |
| LB380 | Analysis of ATP related compounds | InertSustain AQ-C18 |
| LB381 | Analysis of Angiotensin II receptor blockers (InertSustain AQ-C18) | InertSustain AQ-C18 |
| LB382 | Analysis of Angiotensin II receptor blockers (InertSustain C18) | InertSustain C18 |
| LB383 | Analysis of Angiotensin II receptor blockers (InertSustainSwift C18) | InertSustainSwift C18 |
| LB384 | Analysis of Angiotensin II receptor blockers (Inertsil ODS-3) | Inertsil ODS-3 |
| LB385 | Analysis of Angiotensin II receptor blockers (Inertsil ODS-4) | Inertsil ODS-4 |
| LB386 | Analysis of Angiotensin II receptor blockers (Inertsil ODS-SP) | Inertsil ODS-SP |
| LB387 | Analysis of 12 Drugs (InertSustain AQ-C18 HP) | InertSustain AQ-C18 HP |
| LB388 | Analysis of 12 Drugs (InertSustain C18 HP) | InertSustain C18 HP |
| LB389 | Analysis of 12 Drugs (InertSustainSwift C18 HP) | InertSustainSwift C18 HP |
| LB390 | Analysis of 12 Drugs (Inertsil ODS-4) | Inertsil ODS-4 |
| LB391 | Analysis of 12 Drugs (Inertsil ODS-3) | Inertsil ODS-3 |
| LB392 | Analysis of Methacrylic acid (InertSustain AQ-C18) | InertSustain AQ-C18 |
| LB393 | Analysis of Methacrylic acid (InertSustainSwift C18) | InertSustainSwift C18 |
| LB394 | Analysis of Methacrylic acid (InertSustain C18) | InertSustain C18 |
| LB395 | Analysis of Acetaminophen and Caffeine | InertSustainSwift C18 |
| LB396 | Analysis of Oligonucleotide | InertSustainBio C18 |
| LB397 | Analysis of Glyphosate, Glufosinate and AMPA derivatized with 9-Fluorenylmethyl Chloroformate (FMOC) | InertSustainSwift C18 |
| LB398 | Analysis of 9 Drugs (InertSustain AQ-C18) | InertSustain AQ-C18 |
| LB399 | Analysis of 9 Drugs (InertSustainSwift C18) | InertSustainSwift C18 |
| LB400 | Analysis of 9 Drugs (InertSustain C18) | InertSustain C18 |